Cellebrite (NASDAQ: CLBT), a leader in digital investigative solutions, saw its stock plummet 5% in pre-market trading on Thursday following the release of its second-quarter 2025 financial results. The company reported earnings that fell short of analysts' expectations and reduced its full-year revenue guidance.

For the second quarter, Cellebrite posted net income of $19.476 million, significantly below the $25.4 million estimated by analysts. While the company's revenue of $113.276 million slightly exceeded expectations of $112.2 million, it wasn't enough to offset concerns about profitability. The adjusted EBITDA came in at $27.885 million, marginally above the estimated $27 million.

Adding to investor worries, Cellebrite lowered its full-year 2025 revenue guidance to a range of $465 million to $475 million, down from its previous outlook of $470 million to $485 million. This reduction in guidance suggests potential challenges in the company's growth trajectory for the remainder of the year.

Despite the negative market reaction, Cellebrite did report some positive metrics, including a strong gross margin of 84.4% and improved cash flow from operating activities of $32.583 million. The company also announced the appointment of Thomas E. Hogan as CEO, which could bring new strategic direction. However, these positives were overshadowed by the earnings miss and lowered guidance, leading to the sharp stock decline.